Information Provided By:
Fly News Breaks for May 21, 2019
OCUL
May 21, 2019 | 07:15 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Ocular Therapeutix to $9 from $12 after OTX-TP did not meet the primary efficacy endpoint in its Phase 3 glaucoma and ocular hypertension study. The analyst believes it is prudent to remove OTX-TP from his model. He keeps a Buy rating on shares of Ocular Therapeutix.
News For OCUL From the Last 2 Days
There are no results for your query OCUL